Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: A case report in acquired von Willebrand syndrome and review of the literature

Haemophilia

Volumn 21, Issue 4, 2015, Pages 419-429

  Engelen, E T ^a   van Galen, K P M ^a   Schutgens, R E G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Acquired von Willebrand; Angiodysplasia; Gastrointestinal bleed; Monoclonal gammopathy of undetermined significance; Thalidomide

Indexed keywords

BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; DESMOPRESSIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; LENALIDOMIDE; PROPRANOLOL; THALIDOMIDE;

AGED; ANGIODYSPLASIA; BLOOD TRANSFUSION; CASE REPORT; CONSTIPATION; DISEASE ASSOCIATION; DIZZINESS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEMOSTASIS; HEPATIC ENCEPHALOPATHY; HUMAN; LEUKOPENIA; MEDICAL DECISION MAKING; MELENA; MONOCLONAL IMMUNOGLOBULINEMIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRESCRIPTION; PRIORITY JOURNAL; RASH; RELAPSE; REMISSION; REVIEW; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VON WILLEBRAND DISEASE; COMPLICATION; FACTUAL DATABASE; RECURRENT DISEASE; VON WILLEBRAND DISEASES;

AGED; ANGIODYSPLASIA; DATABASES, FACTUAL; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; MELENA; RECURRENCE; THALIDOMIDE; VON WILLEBRAND DISEASES;

EID: 84931955711     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12701     Document Type: Review

References (43)

1. Federici AB, Rand JH, Bucciarelli P et al. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84: 345-9.
2. Collins P, Budde U, Rand JH, Federici AB, Kessler CM. Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome. Haemophilia 2008; 14(Suppl. 3): 49-55.
3. Tiede A. Diagnosis and treatment of acquired von Willebrand syndrome. Thromb Res 2012; 130(Suppl. 2): S2-6.
4. Franchini M, Mannucci PM. von Willebrand disease-associated angiodysplasia: a few answers, still many questions. Br J Haematol 2013; 161: 177-82.
5. Jackson CS, Gerson LB. Management of gastrointestinal angiodysplastic lesions (GIADs): a systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 474-83; quiz 484.
6. Franchini M, Mannucci PM. Gastrointestinal angiodysplasia and bleeding in von Willebrand disease. Thromb Haemost 2014; 112: 427-31.
7. Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood 2011; 117: 6777-85.
8. Federici AB. Use of intravenous immunoglobulin in patients with acquired von Willebrand syndrome. Hum Immunol 2005; 66: 422-30.
9. Junquera F, Saperas E, de Torres I, Vidal MT, Malagelada JR. Increased expression of angiogenic factors in human colonic angiodysplasia. Am J Gastroenterol 1999; 94: 1070-6.
10. Sinha S, Williams JL, Eddington H et al. Small bowel angiodysplasia in a patient on haemodialysis: difficulties in diagnosis and management. BMJ Case Rep 2009. doi: 10.1136/bcr.07.2008.0542.
11. Ge Z, Chen H, Gao Y et al. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology 2011; 141: 1629-37.
12. Garrido A, Sayago M, Lopez J, Leon R, Bellido F, Marquez JL. Thalidomide in refractory bleeding due to gastrointestinal angiodysplasias. Rev Esp Enferm Dig 2012; 104: 69-71.
13. Serrano AG, Leon R, Sayago M, Marquez JL. Thalidomide treatment in cirrhotic patients with severe anemia secondary to vascular malformations. Dig Dis Sci 2012; 57: 1112-3.
14. Chandra Shekar C, Miller MH, Rooke E, Middleton P, Dillon JF. Thalidomide therapy in recurrent gastrointestinal bleeding due to angiodysplasias. J Hepatol 2014; 60: S390.
15. Kamalaporn P, Saravanan R, Cirocco M et al. Thalidomide for the treatment of chronic gastrointestinal bleeding from angiodysplasias: a case series. Eur J Gastroenterol Hepatol 2009; 21: 1347-50.
16. Gossage JR, Chamberlain SM, Sridhar S, Kumar A. An int erim report of thalidomide for treatment of recurrent angioectasia related gastrointestinal bleeding. Haematol Meet Rep 2009; 3: 21.
17. Dabak V, Kuriakose P, Kamboj G, Shurafa M. A pilot study of thalidomide in recurrent GI bleeding due to angiodysplasias. Dig Dis Sci 2008; 53: 1632-5.
18. Bauditz J, Lochs H, Voderholzer W. Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide. Endoscopy 2006; 38: 1036-9.
19. Bauditz J, Schachschal G, Wedel S, Lochs H. Thalidomicle for treatment of severe intestinal bleeding. Gut 2004; 53: 609-12.
20. Wang XY, Chen Y, Du Q. Successful treatment of thalidomide for recurrent bleeding due to gastric angiodysplasia in hereditary hemorrhagic telangiectasia. Eur Rev Med Pharmacol Sci 2013; 17: 1114-6.
21. Tan HH, Ge ZZ, Chen HM, Gao YJ. Successful treatment with thalidomide for a patient with recurrent gastrointestinal bleeding due to angiodysplasia diagnosed by capsule endoscopy. J Dig Dis 2013; 14: 153-5.
22. Alam MA, Sami S, Babu S. Successful treatment of bleeding gastro-intestinal angiodysplasia in hereditary haemorrhagic telangiectasia with thalidomide. BMJ Case Rep 2011. doi: 10.1136/bcr.08.2011.4585.
23. Bowcock SJ. Thalidomide and Lenalidomide to control gastrointestinal bleeding in Hereditary Haemorrhagic Telangiectasia. Br J Haematol 2009; 145: 55.
24. Almadi M, Ghali PM, Constantin A, Galipeau J, Szilagyi A. Recurrent obscure gastrointestinal bleeding: dilemmas and success with pharmacological therapies. Case series and review. Can J Gastroenterol 2009; 23: 625-31.
25. Jimenez-Saenz M, Romero-Vazquez J, Caunedo-Alvarez A, Maldonado-Perez B, Gutierrez JM. Beneficial effects and reversion of vascular lesions by thalidomide in a patient with bleeding portal hypertensive enteropathy. Dig Liver Dis 2010; 42: 232-3.
26. Mimidis K, Kaliontzidou M, Tzimas T, Papadopoulos V. Thalidomide for treatment of bleeding angiodysplasias during hemodialysis. Renal Fail 2008; 30: 1040-1.
27. Alberto SF, Felix J, de Deus J. Thalidomide for the treatment of severe intestinal bleeding. Endoscopy 2008; 40: 788; author reply 789-2008-1077513.
28. Kirkham SE, Lindley KJ, Elawad MA, Blanshard C, Shah N. Treatment of multiple small bowel angiodysplasias causing severe life-threatening bleeding with thalidomide. J Pediatr Gastroenterol Nutr 2006; 42: 585-7.
29. Shurafa M, Kamboj G. Thalidomide for the treatment of bleeding angiodysplasias. Am J Gastroenterol 2003; 98: 221-2.
30. Haider S, Dugdale M. Successful use of thalidomide in two patients with chronic gastrointestinal bleeding due to angiodysplasia. Am J Hematol 2012; 87: S182.
31. Nomikou E, Tsevrenis V, Gafou A, Bellia M, Theodossiades G. Type IIb von Willebrand disease with angiodysplasias and refractory gastrointestinal bleeding successfully treated with thalidomide. Haemophilia 2009; 15: 1340-2.
32. Heidt J, Langers AMJ, van der Meer FJM, Brouwer RE. Thalidomide as treatment for digestive tract angiodysplasias. Neth J Med 2006; 64: 425-8.
33. Hirri HM, Green PJ, Lindsay J. von Willebrand's disease and angiodysplasia treated with thalidomide. Haemophilia 2006; 12: 285-6.
34. Starke RD, Ferraro F, Paschalaki KE et al. Endothelial von Willebrand factor regulates angiogenesis. Blood 2011; 117: 1071-80.
35. Berntorp E, Fuchs B, Makris M et al. Third Aland islands conference on von Willebrand disease, 26-28 September 2012: meeting report. Haemophilia 2013; 19(Suppl. 3): 1-18.
36. Vincentelli A, Susen S, Le Tourneau T et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349: 343-9.
37. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004; 363: 1802-11.
38. Tan H, Chen H, Xu C et al. Role of vascular endothelial growth factor in angiodysplasia: an interventional study with thalidomide. J Gastroenterol Hepatol 2012; 27: 1094-101.
39. Morgan GJ, Davies FE. Role of thalidomide in the treatment of patients with multiple myeloma. Crit Rev Oncol Hematol 2013; 88(Suppl. 1): S14-22.
40. Svetlana Balkanov K, Sotirova T, Genadieva SS, Cevreska L, Stojanovik A, Balkanov T. Adverse effects of thalidomide administration, in patients with myeloma multiplex? Mater Sociomed 2014; 26: 134-6.
41. El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis. A meta-analysis. Thromb Haemost 2007; 97: 1031-6.
42. Rajkumar SV. Second to none. Blood 2012; 120: 1537-9.
43. Witzig TE, Laumann KM, Lacy MQ et al. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia 2013; 27: 220-5.